ESMO GI 2019: colon cancer survival in patients with obesity and hyperglycaemia


  • Mary Corcoran
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

The presence of obesity and hyperglycaemia in patients with colon adenocarcinoma clinical stage (CS) I-III is linked with increased mortality risk and reduced disease-free survival (DFS), according to new research presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2019

In a bid to determine the implications of obesity and hyperglycaemia on DFS and overall survival (OS), researchers examined data on 715 patients with CS I-III adenocarcinoma of the colon. All of the patients were treated with surgery+/-adjuvant chemotherapy. 

A total of 45 per cent (n=323) of patients presented with obesity/overweight, while hyperglycaemia was observed in 57 per cent (n=406) of patients. 

The study found patients with hyperglycaemia had a five-year DFS of 66 per cent versus 80 per cent for normoglycaemic patients (P=.001). Comparing body weight, five-year DFS was 72 per cent in both obesity/overweight and normal weight groups (P=.694). 

Patients with hyperglycaemia had a five-year OS of 73 per cent versus 83 per cent for patients with normoglycaemia (P=.047). Patients with obesity/overweight had a five-year OS of 67 per cent versus 86 per cent for patients with normoweight (P=.001).